[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100328173":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":25,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":25,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":25,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tranexamic Acid","EXPERIMENTAL","5-day course of standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg\u002Fday) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)",[13],"Drug: Tranexamic Acid",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","5-day course of placebo and intravenous saline during ACL reconstruction surgery",[19],"Drug: Placebos",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","5-day course of oral standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg\u002Fday) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebos","5-day course of oral placebo and intravenous saline during ACL reconstruction surgery",[15],[31],{"name":32,"affiliation":5,"role":33},"Constance Chu, MD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Christine L Hoang, BS","CONTACT","650-721-7612","c1hoang@stanford.edu",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Stanford","California","94305","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-122.16608,37.42411,{"lat":52,"lon":51},[55],{"name":56,"role":37,"phone":38,"phoneExt":25,"email":39},"Christine Hoang",{"type":33,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Constance R. Chu, MD","Principal Investigator",[61],{"name":62,"class":63},"United States Department of Defense","FED","100328173","phase-2-the-effects-of-tranexamic-acid-on-joint-inflammation-and-cartilage-health-in-anterior-cruciate-ligament-injured-patients-100328173",false,"NCT03552705","The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients","Novel Strategies to Combat Post-Traumatic Osteoarthritis (PTOA):The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients","Inclusion Criteria:\n\n* age 18-30 years\n* within 4 days of unilateral ACL injury\n* presence of effusion\u002Fhemarthrosis.\n\nExclusion Criteria:\n\n* inflammatory arthritis, radiographic osteoarthritis (K-L Grade 2 or higher), gout\u002F pseudogout\n* systemic or acute illness requiring medications\n* concomitant knee injury aside from meniscus tear and MCL tear not requiring surgery\n* prior surgery to either knee\n* prior injury to either knee requiring crutches\n* history of thromboembolic disease\n* current use of combination hormonal contraception\n* chronic NSAID use\n* cortisone injection to either knee within the prior 3 months\n* not indicated for or unable to undergo ACLR within 3 months of injury","ALL","18 Years","30 Years",{"count":75,"type":76},50,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","Patients who tear their ACL are at high risk for developing arthritis (post-traumatic osteoarthritis-PTOA) just 10 years later. Joint bleeding and inflammation contribute to deterioration of joint health. This study will determine whether treatment with Tranexamic Acid (TXA), an FDA approved medication that reduces bleeding right after ACL injury and reconstructive surgery reduces inflammation and improves joint health as a new strategy to prevent or delay the onset of PTOA.",[82],"Anterior Cruciate Ligament Reconstruction","2026-02-25",{"date":85,"type":86},"2026-02-27","ACTUAL",{"date":88,"type":86},"2019-08-01",{"date":90,"type":76},"2027-01-14",{"name":5,"class":6},1]